177Lu-AKIR001

N/A

Report date: 2025/09/19 16:19:20

Base Information

Drug Name177Lu-AKIR001
Drug Alias Name177Lu-AKIR001
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionCD44 antigen modulators
TargetsCD44 antigen
Therapy Area/IndicationsVulvar NeoplasmsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAkiram Therapeutics AB
China Registration ClassN/A

Develop Information

Active CompaniesUppsala UniversityKarolinska Institutet
Inactive CompaniesAkiram Therapeutics AB
Active IndicationsVulvar NeoplasmsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A